Organization
Reggio Emilia
3 abstracts
Abstract
Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016).Org: Reggio Emilia, Potenza, Italy - Reggio Emilia, Vimercate, Experimental Clinical Abdominal Oncology Unit,
Abstract
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.Org: Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori – IRCCS Fondazione G. Pascale, Napoli, Italy, Istituto Nazionale Tumori-IRCCS Fondazione G. Pascale, Istituto Nazionale Tumori - IRCCS Fondazione Pascale, Medical Oncology Unit. Comprehensive Cancer Center. AUSL-IRCCS Reggio Emilia, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial.Org: University of Padua School of Medicine, Veneto Institute of Oncology IOV-IRCCS Padua, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Department of Oncology, Hematology, and Respiratory Diseases, Modena University,